Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome
Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR
Published in Alimentary Pharmacology & Therapeutics
Methodology
12-week randomised, double-blind, placebo-controlled crossover trial of trans-galactooligosaccharide 3.5 g or 7 g daily in adults with IBS
Key Findings
GOS significantly increased faecal bifidobacteria and improved stool consistency, flatulence, bloating and subjective global assessment; anxiety scores improved at the higher dose.
Conclusions
GOS acts as an effective prebiotic and improved several IBS symptoms in this trial.
Limitations
Single centre; manufacturer-affiliated authors; crossover design with modest sample.
Supplements Studied
The prebiotic significantly enhanced faecal bifidobacteria and improved stool consistency, flatulence, bloating and subjective global assessment in irritable bowel syndrome.
Outcomes Measured
The trans-galactooligosaccharide prebiotic significantly enhanced faecal bifidobacteria concentrations.
GOS significantly increased faecal bifidobacteria and improved stool consistency, flatulence, bloating and subjective global assessment; anxiety scores improved at the higher dose.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.